Managed Financial Conflicts of Interest (FCOIs) with Research Funded by the Public Health Service (PHS)

Current as of August 12, 2022

1.

**Date Disclosed:** April 22, 2013  
**Investigator with FCOI:** William Federspiel, Ph.D.  
**Title:** Professor of Chemical Engineering, Surgery and Bioengineering  
**PHS Funding:** NIH 1 R01 HL117637-01 *Paracorporeal Ambulatory Assist Lung*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** ALung Technologies, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh; consulting; reimbursed/sponsored travel; equity interest  
**Approximate dollar value of the SFI:** Consulting income and reimbursed/sponsored travel between $20,000 – $39,000; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

2.

**Date Disclosed:** August 19, 2013  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 4 R37 HL058115-17 *Redox Transduction of Nitric Oxide Signaling*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
3. **Date Disclosed:** August 19, 2013  
**Investigator with FCOI:** Francisco Schopfer, Ph.D.  
**Title:** Research Associate Professor of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 4 R37 HL058115-17 *Redox Transduction of Nitric Oxide Signaling*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.  
**Approximate dollar value of the SFI:** Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

4. *FCOI eliminated August 31, 2018*  

5. **Date Disclosed:** July 31, 2014  
**Investigator with FCOI:** Stephen H. Thorne, Ph.D.  
**Title:** Assistant Professor of Cell Biology  
**PHS Funding:** NIH 1 R01 CA178766-01A1 *Creation of Immuno-Oncolytic Viruses for Cancer Therapy*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Western Oncolytics  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Western Oncolytics; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

5. **Date Disclosed:** February 17, 2015  
**Investigator with FCOI:** Lee M. Ritterband, Ph.D.  
**Title:** Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia  
**PHS Funding:** NIH 4 UH 3HL125103-01 *Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** BeHealth Solutions, LLC  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

6. **Date Disclosed:** March 20, 2015  
**Investigator with FCOI:** Mark H. Yazer, M.D.
Title: Professor of Pathology  
**PHS Funding:** NIH HHSN 268201100004 *Recipient Epidemiology and Donor Evaluation Study-III (REDS-III)*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Octapharma  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $5,000 – $9,999

---

**7.**

**Date Disclosed:** April 30, 2015  
**Investigator with FCOI:** Louis D. Falo, Jr., M.D., Ph.D.  
**Title:** Professor and Chair of Dermatology  
**PHS Funding:** 5 P50 CA121973-07 (Sub-project ID: 7388) *SPORE in Skin Cancer*  
**Role on Research Project:** Principal Investigator of bench and animal, and Co-Investigator of human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** SkinJect  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**8.**

**Date Disclosed:** May 14, 2015  
**Investigator with FCOI:** Saul Shiffman, Ph.D.  
**Title:** Professor of Psychology  
**PHS Funding:** NIH 5 R01 DA034629-02 *Cessation in Non-Daily Smokers: a RCT of NRT with Ecological Momentary Assessment*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Reynolds American, Inc.; Niconovum (a subsidiary of Reynolds American, Inc.); JSR, LLC  
**Nature of the SFI:** Consulting with Reynolds American and Niconovum; reimbursed/sponsored travel from Reynolds American; intellectual property rights (e.g., royalties, patents, copyrights) assigned to JSR; equity interest in JSR  
**Approximate dollar value of the SFI:** Consulting income between $500,000 - $549,999; reimbursed/sponsored travel between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**9.**  
*FCOI eliminated June 7, 2019*

**Date Disclosed:** May 28, 2015  
**Investigator with FCOI:** Dario Vitturi, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH R37 HL058115 *Redox transduction of nitric oxide signaling*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

10. FCOI eliminated June 13, 2019

Date Disclosed: August 11, 2015
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH R37 HL058115 Redox transduction of nitric oxide signaling
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

11.

Date Disclosed: August 13, 2015
Investigator with FCOI: Francisco Schopfer, Ph.D.
Title: Research Associate Professor of Pharmacology and Chemical Biology
PHS Funding: NIH 1 R01 AR066548-01A1 The Immunoregulatory Effects of Electrophilic Fatty acids on Psoriasis
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Complexa, Inc.
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

12. FCOI eliminated April 12, 2019

Date Disclosed: August 18, 2015
Investigator with FCOI: Mark Gladwin, M.D.
Title: Professor and Chair of Medicine
PHS Funding: NIH 1 K23 HL124051-01A1 Nitrite Modulation of Hypertension, Platelet Activation and Mitochondrial Function
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: National Institutes of Health
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to Mast Therapeutics
Approximate dollar value of the SFI: $1 -$4,999
13. **FCOI eliminated August 25, 2016**

**Date Disclosed:** February 3, 2016  
**Investigator with FCOI:** Fuchiang (Rich) Tsui, Ph.D.  
**Title:** Research Assistant Professor of Biomedical Informatics  
**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Vertvality  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

14. **FCOI eliminated April 26, 2017**

**Date Disclosed:** February 8, 2016  
**Investigator with FCOI:** James Eles  
**Title:** Graduate Student, Department of Bioengineering  
**PHS Funding:** NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

15. **FCOI eliminated April 26, 2017**

**Date Disclosed:** February 8, 2016  
**Investigator with FCOI:** Xinyan (Tracy) Cui  
**Title:** Professor of Bioengineering  
**PHS Funding:** NIH R01 NS062019 *Biomimetic Surfaces for Neural Implants*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

16. **FCOI eliminated July 14, 2017**

**Date Disclosed:** February 12, 2016  
**Investigator with FCOI:** Edward Prochownik, M.D., Ph.D.  
**Title:** Professor of Pediatrics and Microbiology & Molecular Genetics  
**PHS Funding:** NIH 1 US4 CA199092-01 *Center for Multiple Myeloma Nanotherapy*
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: February 22, 2016
Investigator with FCOI: Andrew Hinck, Ph.D.
Title: Visiting Professor of Structural Biology
PHS Funding: NIH R01 CA172886 Inhibition of the Tumor-Promoting Effects of TGF-Beta in Advanced Prostate Cancer
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Texas Health Science Center at San Antonio
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Texas Health Science Center at San Antonio
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

FCOI eliminated August 8, 2018

Date Disclosed: April 25, 2016
Investigator with FCOI: Rebecca Jacobson, M.D., M.S.
Title: Professor of Biomedical Informatics and Pathology
PHS Funding: NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: NEXI
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

FCOI eliminated August 8, 2018

Date Disclosed: April 25, 2016
Investigator with FCOI: Girish Chavan
Title: Staff, Department of Biomedical Informatics
PHS Funding: NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: NEXI
**Nature of the SFI:** Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

20. *FCOI eliminated August 8, 2018*

**Date Disclosed:** April 25, 2016  
**Investigator with FCOI:** Eugene Tseytlin  
**Title:** Staff, Department of Biomedical Informatics  
**PHS Funding:** NIH U24 CA180921 Advanced Development of TIES-Enhancing Access to Tissue for Cancer Research  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** NEXI  
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to NEXI  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

21. *FCOI eliminated June 7, 2019*

**Date Disclosed:** May 16, 2016  
**Investigator with FCOI:** Dario Vitturi, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH U01 HL117721 Cellular and Molecular Mechanisms of Acute Lung Injury in Sickle Cell Disease  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

22.

**Date Disclosed:** June 9, 2016  
**Investigator with FCOI:** Joseph Glorioso, Ph.D.  
**Title:** Professor, Department of Microbiology & Molecular Genetics  
**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas  
**Role on Research Project:** Principal Investigator of bench research and Co-Investigator of animal research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus  
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus
**Approximate dollar value of the SFI:** Consulting income between $100,000 - $149,999; equity interest between $450,000 - $499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

23.

**Date Disclosed:** June 9, 2016  
**Investigator with FCOI:** Paola Grandi, Ph.D.  
**Title:** Assistant Professor, Department of Neurological Surgery  
**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus  
**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus  
**Approximate dollar value of the SFI:** Consulting income between $100,000 - $149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

24.

**Date Disclosed:** June 9, 2016  
**Investigator with FCOI:** Justus Cohen, Ph.D.  
**Title:** Research Instructor, Department of Microbiology & Molecular Genetics  
**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

25.

**Date Disclosed:** June 9, 2016  
**Investigator with FCOI:** William Goins, Ph.D.  
**Title:** Research Assistant Professor, Department of Microbiology & Molecular Genetics  
**PHS Funding:** NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*  
**Role on Research Project:** Principal Investigator and Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Oncorus  
**Nature of the SFI:** Consulting; equity interest  
**Approximate dollar value of the SFI:** Consulting income between $5,000 - $9,999; equity interest between $5,000 - $9,999.
26.

Date Disclosed: June 9, 2016  
Investigator with FCOI: Nduka Amankulor, M.D.  
Title: Assistant Professor, Department of Neurological Surgery  
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) *Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas*  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus  
Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus  
Approximate dollar value of the SFI: Consulting income between $5,000 - $9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

27.  
*FCOI eliminated November 30, 2018*  

Date Disclosed: June 13, 2016  
Investigator with FCOI: Paola Grandi, Ph.D.  
Title: Assistant Professor, Department of Neurological Surgery  
PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus  
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus  
Approximate dollar value of the SFI: Consulting income between $100,000 - $149,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

28.

Date Disclosed: June 13, 2016  
Investigator with FCOI: William Goins, Ph.D.  
Title: Research Assistant Professor, Department of Microbiology & Molecular Genetics  
PHS Funding: NIH R01 CA175052 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus  
Nature of the SFI: Consulting; equity interest  
Approximate dollar value of the SFI: Consulting income between $5,000 - $9,999; equity interest between $5,000 - $9,999.

29.

Date Disclosed: June 13, 2016  
Investigator with FCOI: Nduka Amankulor, M.D.
Title: Assistant Professor, Department of Neurological Surgery  
PHS Funding: NIH R01 CA175052 Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus  
Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus  
Approximate dollar value of the SFI: Consulting income between $5,000 - $9,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

30. **FCOI eliminated October 3, 2016**

Date Disclosed: June 28, 2016  
Investigator with FCOI: Michael McClincy, M.D.  
Title: Fellow, Massachusetts General Hospital  
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

31.

Date Disclosed: June 28, 2016  
Investigator with FCOI: Kevin Bell, Ph.D.  
Title: Research Assistant Professor, Department of Orthopaedic Surgery  
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

32. **FCOI eliminated August 25, 2016**

Date Disclosed: June 28, 2016  
Investigator with FCOI: Robert Hartman, Ph.D.  
Title: Postdoctoral Associate, Department of Physical Medicine & Rehabilitation  
PHS Funding: NIH 5 TL1 TR000145-10 University of Pittsburgh Clinical and Translational Science Institute  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Impellia

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

33.  
*FCOI eliminated September 2, 2016*

**Date Disclosed:** June 28, 2016

**Investigator with FCOI:** Xinyan (Tracy) Cui

**Title:** Professor of Bioengineering

**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

34.  
*FCOI eliminated September 2, 2016*

**Date Disclosed:** June 28, 2016

**Investigator with FCOI:** James Eles

**Title:** Graduate Student, Department of Bioengineering

**PHS Funding:** NIH 5 TL1 TR000145-10 *University of Pittsburgh Clinical and Translational Science Institute*

**Role on Research Project:** Co-Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Interphase Materials

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

35.  
*FCOI eliminated July 19, 2017*

**Date Disclosed:** July 1, 2016

**Investigator with FCOI:** Joel S. Greenberger, M.D.

**Title:** Professor and Chair of Radiation Oncology

**PHS Funding:** NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh

**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh

**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
36.  **FCOI eliminated July 19, 2017**

**Date Disclosed:** July 1, 2016  
**Investigator with FCOI:** Michael W. Epperly, Ph.D.  
**Title:** Associate Professor of Radiation Oncology  
**PHS Funding:** NIH 2 U19 AI068021-11 *Signature-Directed, Sequential Delivery of Radiation Mitigators*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

37.  **FCOI eliminated August 4, 2017**

**Date Disclosed:** July 5, 2016  
**Investigator with FCOI:** Shivalingappa Swamynathan, Ph.D.  
**Title:** Associate Professor of Opthalmology and Cell Biology  
**PHS Funding:** NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

38.  **FCOI eliminated August 4, 2017**

**Date Disclosed:** July 5, 2016  
**Investigator with FCOI:** Sudha Swamynathan  
**Title:** Research Technician, Department of Opthalmology  
**PHS Funding:** NIH 5 R01 EY022898-03 *Corneal Expression and Function of Slurp1*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

39.  **FCOI eliminated July 6, 2020**

**Date Disclosed:** July 13, 2016  
**Investigator with FCOI:** Yuri Nikiforov, M.D., Ph.D.  
**Title:** Professor of Pathology  
**PHS Funding:** NIH 2 P50 CA097190-11 *Head and Neck Cancer SPORE*
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to UPMC
Approximate dollar value of the SFI: $100,000-$149,999

Date Disclosed: July 14, 2016
Investigator with FCOI: Bruce Freeman, Ph.D.
Title: Professor and Chair of Pharmacology and Chemical Biology
PHS Funding: NIH 1 R21 AI122071-01A1 The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

FCOI eliminated June 13, 2019

Date Disclosed: July 14, 2016
Investigator with FCOI: Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH 1 R21 AI122071-01A1 The Effects of Nitrate/Nitrite and Conjugated Linoleic Acid Supplementation on the Obese Asthmatic Pathology
Role on Research Project: Principal Investigator of bench, and Co-Investigator on human subject, research
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

FCOI eliminated May 4, 2020

Date Disclosed: August 9, 2016
Investigator with FCOI: Dario A. Vignali, Ph.D.
Title: Professor and Vice Chair of Immunology
PHS Funding: NIH 9 R01 CA203689-07A1 Interleukin-35 and the Tumor Microenvironment
Role on Research Project: Principal Investigator of bench, and Co-Investigator on non-bench, research
Name of Entity in which Significant Financial Interest (SFI) is held: Tizona Therapeutics
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the St. Jude Children’s Research Hospital and licensed to Tizona Therapeutics;
Approximate dollar value of the SFI: Consulting income between $60,000 - $79,999; licensing proceeds from intellectual property rights between $10,000 - $19,999; equity interest is SFI whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

43.  
FCOI eliminated July 14, 2021

Date Disclosed: August 23, 2016
Investigator with FCOI: Bruce Freeman, Ph.D.
Title: Professor and Chair of Pharmacology and Chemical Biology
PHS Funding: NIH 1 K01 HL133331-01 Protection against sickle cell disease nephropathy by nitrated fatty acids
Role on Research Project: Primary Mentor
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

44.  
FCOI eliminated June 7, 2019

Date Disclosed: August 23, 2016
Investigator with FCOI: Dario Vitturi, Ph.D.
Title: Research Instructor, Department of Pharmacology & Chemical Biology
PHS Funding: NIH 1 K01 HL133331-01 Protection against sickle cell disease nephropathy by nitrated fatty acids
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

45.  
FCOI eliminated July 14, 2021

Date Disclosed: August 23, 2016
Investigator with FCOI: Francisco Schopfer, Ph.D.
Title: Research Associate Professor of Pharmacology and Chemical Biology
PHS Funding: NIH 1 K01 HL133331-01 Protection against sickle cell disease nephropathy by nitrated fatty acids
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting; equity interest; Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

46.  
**FCOI eliminated June 13, 2019**

**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

47.  
**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

48.  
**FCOI eliminated April 27, 2018**

**Date Disclosed:** September 1, 2016  
**Investigator with FCOI:** Steven Woodcock, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 1 R01 HL132550-01 *Anti-inflammatory Lipid Mediators in Asthma*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

49.  
**FCOI eliminated April 12, 2019**

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Mark Gladwin, M.D.
**Title:** Professor and Chair of Medicine  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** National Institutes of Health  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the National Institutes of Health and licensed to MAST Therapeutics  
**Approximate dollar value of the SFI:** $5,000 - $9,999

**50. FCOI eliminated May 25, 2021**

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Bruce Freeman, Ph.D.  
**Title:** Professor and Chair of Pharmacology and Chemical Biology  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Principal Investigator of bench research and Co-Investigator of human subject research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

**51. FCOI eliminated June 13, 2019**

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.  
**Title:** Research Assistant Professor of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999

**52. FCOI eliminated April 27, 2018**

**Date Disclosed:** September 19, 2016  
**Investigator with FCOI:** Steven Woodcock, Ph.D.  
**Title:** Research Instructor, Department of Pharmacology & Chemical Biology  
**PHS Funding:** NIH 2 P01 HL103455-06 *Therapeutic Targeting of Vascular Subphenotypes of Lung Disease*  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Complexa, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $10,000 - $19,999
53. **FCOI eliminated March 20, 2018**

**Date Disclosed:** September 23, 2016  
**Investigator with FCOI:** Matthew Neal, M.D.  
**Title:** Assistant Professor of Surgery and Critical Care Medicine  
**PHS Funding:** NIH 1 R35 GM119526-01 *Mechanistic Elucidation and Targeted Therapy of Platelet Dysfunction After Trauma*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

54. **FCOI eliminated March 29, 2017**

**Date Disclosed:** September 23, 2016  
**Investigator with FCOI:** Brian Suffoletto, M.D.  
**Title:** Assistant Professor of Emergency Medicine  
**PHS Funding:** NIH 1 R01 AA23650-01A1 *Mechanisms of Change for an Effective Alcohol Text Message Intervention*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to healthStratica  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

55. **Date Disclosed:** September 27, 2016  
**Investigator with FCOI:** Patricia Opresko, Ph.D.  
**Title:** Associate Professor of Environmental and Occupational Health  
**PHS Funding:** NIH 2 R44 GM108187-03 *GammaPNA Miniprobes for Telomere Analysis and RNA FISH*  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to PNA Innovations, Inc.  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

56. **FCOI eliminated June 13, 2019**

**Date Disclosed:** October 5, 2016  
**Investigator with FCOI:** Stacy Gelhaus Wendell, Ph.D.
Title: Research Assistant Professor of Pharmacology & Chemical Biology
PHS Funding: NIH 1 U54 DK112079-01 University of Pittsburgh O'Brien Cooperative Research Center Program
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: October 10, 2016
Investigator with FCOI: Guergana Savova, Ph.D.
Title: Associate Professor of Pediatrics, Harvard Medical School and Computational Health Informatics Program at Boston Children’s Hospital
PHS Funding: NIH 5 U24 CA184407-03 Cancer Deep Phenotype Extraction from Electronic Medical Records
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Wired Informatics, LLC
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

FCOI eliminated June 17, 2021

Date Disclosed: October 18, 2016
Investigator with FCOI: John Kellum, M.D.
Title: Professor and Vice Chair for Research, Department of Critical Care Medicine
PHS Funding: NIH 1 R01 DK106256-01A1 Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: bioMérieux and Astute Medical (a subsidiary of bioMerieux)
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $20,000 - $39,999

FCOI eliminated July 19, 2017

Date Disclosed: October 25, 2016
Investigator with FCOI: Alexander Deiters, Ph.D.
Title: Professor of Chemistry
PHS Funding: NIH 1 R21 HD 85206-01A1 Optical Control of Translation and Gene Editing in Zebrafish Embryos
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: North Carolina State University
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to North Carolina State University

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

60.

Date Disclosed: October 26, 2016
Investigator with FCOI: Bonnie Hall, Ph.D.
Title: Research Instructor, Department of Microbiology & Molecular Genetics
PHS Funding: NIH P01 CA163205 (Sub-project ID: 7345) Circumventing Barriers to Effective Oncolytic Virotherapy of Malignant Gliomas
Role on Research Project: Co-Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Oncorus
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

61. FCOI eliminated April 30, 2018

Date Disclosed: November 2, 2016
Investigator with FCOI: Mary Loghmani, P.T., Ph.D.
Title: Associate Professor of Physical Therapy, Indiana University
PHS Funding: NIH 5 P2C HD086843-02 Alliance for Regenerative Rehabilitation Research & Training (AR3T)
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: Health Smart Technologies, Inc.
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

62. FCOI eliminated March 3, 2018

Date Disclosed: November 17, 2016
Investigator with FCOI: Maliha Zahid, M.D., Ph.D.
Title: Research Instructor, Department of Developmental Biology
PHS Funding: NIH 1 UL1 TR 001857-01 University of Pittsburgh Clinical and Translational Science Institute
Role on Research Project: Principal Investigator
Name of Entity in which Significant Financial Interest (SFI) is held: University of Pittsburgh
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
63.

**Date Disclosed:** January 4, 2017  
**Investigator with FCOI:** Lee M. Ritterband, Ph.D.  
**Title:** Professor of Psychiatry and Neurobehavioral Sciences, University of Virginia  
**PHS Funding:** NIH 1 R03 HL135213-01 Feasibility and Acceptability of an internet-based cognitive-behavioral treatment for insomnia in adults with asthma  
**Role on Research Project:** Consultant  
**Name of Entity in which Significant Financial Interest (SFI) is held:** BeHealth Solutions, LLC  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Virginia and licensed to BeHealth Solutions, LLC; equity interest  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

64.

**Date Disclosed:** January 17, 2017  
**Investigator with FCOI:** Yadong Wang, Ph.D.  
**Title:** Professor, Department of Bioengineering  
**PHS Funding:** NIH 7 R21 EB016774-03 Biomimetic Coacervate Delivery of Muscle Stem Cell to Improve Cardiac Repair  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** University of Pittsburgh  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh  
**Approximate dollar value of the SFI:** The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

65.

**Date Disclosed:** March 2, 2017  
**Investigator with FCOI:** Kenneth W. Kinzler, PhD  
**Title:** Professor of Oncology, Johns Hopkins University  
**PHS Funding:** NIH 2 U01 CA152753-06 ctDNA for the Early Detection and Monitoring of Colorectal Cancer  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Sysmex Corporation  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University and licensed to Sysmex Corporation; payment for services  
**Approximate dollar value of the SFI:** Intellectual property royalty distributions between $60,000-$79,999; payment for services between $60,000-$79,999
66.

**Date Disclosed:** June 21, 2017

**Investigator with FCOI:** Joseph Glorioso, PhD

**Title:** Professor of Microbiology & Molecular Genetics

**PHS Funding:** NIH 5 R01 CA175052-04 *Enhanced GBM Therapy Using a New Class of HSV Oncolytic Vector*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Oncorus

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** Consulting income between $100,000 - $149,999; equity interest between $450,000 - $499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

67.

**Date Disclosed:** July 26, 2017

**Investigator with FCOI:** Beibei Bill Chen, PhD

**Title:** Associate Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine

**PHS Funding:** NIH 5 UH3 HL123502 *A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Koutif Therapeutics

**Nature of the SFI:** equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics

**Approximate dollar value of the SFI:** Consulting income between $20,000 - $39,999; intellectual property rights and equity interests are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

68.

**Date Disclosed:** July 26, 2017

**Investigator with FCOI:** Rama K. Mallampalli, MD

**Title:** Division Chief, Division of Pulmonary, Allergy, and Critical Care Medicine

**PHS Funding:** NIH 5 UH3 HL123502 *A New Genus of Ubiquitin-Based Anti-Inflammatories for COPD*

**Role on Research Project:** Principal Investigator of bench, and Co-Investigator of animal, research

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Koutif Therapeutics

**Nature of the SFI:** equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Koutif Therapeutics

**Approximate dollar value of the SFI:** Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Date Disclosed: July 26, 2017  
Investigator with FCOI: Xiang-Qun (Sean) Xie, PhD, EMBA  
Title: Associate Dean for Research Innovation and Professor, Department of Pharmaceutical Sciences  
PHS Funding: NIH 1 R44 CA210882 SQSTM1/P62-Targeted Small Molecules for Multiple Myeloma Disease  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: ID4Pharma, LLC  
Nature of the SFI: equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned/licensed to ID4Pharma  
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

70.

Date Disclosed: August 9, 2017  
Investigator with FCOI: John M. Kirkwood, MD  
Title: Professor of Medicine, Division of Hematology/Oncology  
PHS Funding: NIH 5 U01 CA180820 ECOG-ACRIN Operations Center  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Novartis  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $10,000 - $19,999

71.

Date Disclosed: October 12, 2017  
Investigator with FCOI: Steven Moulton, MD  
Title: Professor of Surgery, University of Colorado School of Medicine  
PHS Funding: NIH 7 UM1 HL120877 Analysis and Characterization of Trauma-Induced Coagulopathy  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Flashback Technologies, Inc.  
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Colorado and licensed to Flashback Technologies, Inc.; equity interest; consulting; management position  
Approximate dollar value of the SFI: Consulting income between $10,000-$19,999; intellectual property rights between $10,000-$19,999; management position is unpaid; equity interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

72.

Date Disclosed: November 8, 2017  
Investigator with FCOI: Francisco Schopfer, Ph.D.
Title: Research Associate Professor of Pharmacology and Chemical Biology  
PHS Funding: NIH 5 R01 HL132550 Anti-Inflammatory Lipid Mediators in Asthma  
Role on Research Project: Co-Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Complexa, Inc.  
Nature of the SFI: Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Alabama, Birmingham and/or the University of Pittsburgh and licensed to Complexa, Inc.  
Approximate dollar value of the SFI: Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: November 15, 2017  
Investigator with FCOI: Ling Wang, MD, PhD  
Title: Research Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine  
PHS Funding: NIH 5 R01 HL125886 Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.  
Nature of the SFI: Equity interest  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: November 15, 2017  
Investigator with FCOI: Charles F. McTiernan, PhD  
Title: Research Associate Professor of Medicine, Division of Cardiology  
PHS Funding: NIH 5 R01 HL125886 Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.  
Nature of the SFI: Equity interest  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: November 16, 2017  
Investigator with FCOI: Jesus Tejero Bravo, PhD  
Title: Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine  
PHS Funding: NIH 5 R01 HL125886 Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.  
**Approximate dollar value of the SFI:** Management position income between $5,000 - $9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** November 16, 2017  
**Investigator with FCOI:** Jason J. Rose, MD, MBA  
**Title:** Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine  
**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.  
**Approximate dollar value of the SFI:** Management positions income between $10,000-$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** November 16, 2017  
**Investigator with FCOI:** Mark T. Gladwin, MD  
**Title:** Chair, Department of Medicine  
**PHS Funding:** NIH 5 R01 HL125886 *Antidote for Inhaled CO Poisoning Based on Mutationally Engineered Neuroglobin*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.  
**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** November 20, 2017  
**Investigator with FCOI:** Jesus Tejero Bravo, PhD  
**Title:** Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine  
**PHS Funding:** NIH 5 R21 ES027390 *Countermeasure Therapeutics for Acute Lung Injury*
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.
Approximate dollar value of the SFI: Management position income between $5,000 - $9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: January 26, 2018
Investigator with FCOI: John Kellum, MD
Title: Professor and Vice Chair for Research, Department of Critical Care Medicine
PHS Funding: NIH 1 R21 DK113486 Biochemical and Reno-Protective Effects of Remote Ischemic Preconditioning on Contrast-Induced Kidney Disease
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: bioMérieux and Astute Medical (a subsidiary of bioMerieux)
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $20,000 - $39,999

Date Disclosed: March 5, 2018
Investigator with FCOI: Stephen F. Badylak, DVM, PhD, MD
Title: Professor, Department of Surgery and Deputy Director of the McGowan Institute for Regenerative Medicine (MIRM)
PHS Funding: NIH 5 F31 CA210694 Understanding Esophageal Adenocarcinoma Progression Using Inflammatory and Neoplastic Extracellular Matrix Hydrogels
Role on Research Project: Primary Mentor
Name of the Entity in which Significant Financial Interest (SFI) is held: ECM Therapeutics, Inc. (formerly Restoure, Inc.)
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ECM Therapeutics, Inc. (formerly Restoure, Inc.).
Approximate dollar value of the SFI: Management position income between $100,000 - $149,999; equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: June 19, 2018
Investigator with FCOI: Dario A. Vignali, PhD
Title: Professor and Vice Chair, Department of Immunology
**PHS Funding**: NIH 1 R01 CA228181-01A1 *Targeting TIGIT and PD-1 in Melanoma*

**Role on Research Project**: Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held**: Potenza Therapeutics, Inc.

**Nature of the SFI**: Equity interest

**Approximate dollar value of the SFI**: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed**: June 19, 2018

**Investigator with FCOI**: Dario A. Vignali, PhD

**Title**: Professor and Vice Chair, Department of Immunology

**PHS Funding**: NIH 1 R01 CA228181-01A1 *Targeting TIGIT and PD-1 in Melanoma*

**Role on Research Project**: Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held**: Bristol-Myers Squibb, Inc.

**Nature of the SFI**: Equity interest; consulting

**Approximate dollar value of the SFI**: Aggregate of equity interest and consulting income between $40,000 - $59,999

---

**Date Disclosed**: July 2, 2018

**Investigator with FCOI**: Jason J. Rose, MD, MBA

**Title**: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

**PHS Funding**: NIH 1 K08 HL136857-01A1 *Discovering and Developing Recombinant Molecular Scavenging Agents for the Treatment of Carbon Monoxide Induced Cardiovascular Dysfunction*

**Role on Research Project**: Principal Investigator of bench, and Co-Investigator of animal research

**Name of the Entity in which Significant Financial Interest (SFI) is held**: Globin Solutions, Inc.

**Nature of the SFI**: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.

**Approximate dollar value of the SFI**: Management positions income between $10,000-$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed**: August 13, 2018

**Investigator with FCOI**: Chakra Chennubhotla, PhD

**Title**: Associate Professor, Department of Computational and Systems Biology

**PHS Funding**: NIH 5 U01 CA204826-03 *Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images*

**Role on Research Project**: Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held**: SplIntellx, Inc.

**Nature of the SFI**: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SplIntellx, Inc.
Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

85.

Date Disclosed: August 13, 2018
Investigator with FCOI: D. Lansing Taylor, PhD
Title: Distinguished Professor, Department of Computational and Systems Biology and Director, University of Pittsburgh Drug Discovery Institute
PHS Funding: NIH 5 U01 CA204826-03 Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images
Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: SpIntellx, Inc.
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SpIntellx, Inc.
Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

86.

Date Disclosed: August 13, 2018
Investigator with FCOI: Jeffrey L. Fine, MD
Title: Assistant Professor, Department of Pathology
PHS Funding: NIH 5 U01 CA204826-03 Informatics Tools for Tumor Heterogeneity in Multiplexed Fluorescence Images
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: SpIntellx, Inc.
Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SpIntellx, Inc.
Approximate dollar value of the SFI: The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

87.

Date Disclosed: October 24, 2018
Investigator with FCOI: Edith Tzeng, MD
Title: Professor, Department of Surgery
PHS Funding: NIH 1 R56 HL142743-01 Engineering Biologic Topography into Vascular Grafts
Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Aruga Technologies, LLC
**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Aruga Technologies, LLC

**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**88.**

**Date Disclosed:** October 24, 2018  
**Investigator with FCOI:** Sachin Velankar, PhD  
**Title** Associate Professor, Department of Chemical and Petroleum Engineering  
**PHS Funding:** NIH 1 R56 HL142473-01 *Engineering Biologic Topography into Vascular Grafts*  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Aruga Technologies, LLC  
**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Aruga Technologies, LLC  
**Approximate dollar value of the SFI:** The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**89.**  
**FCOI eliminated January 30, 2019**

**Date Disclosed:** November 29, 2018  
**Investigator with FCOI:** Steven R. Little, PhD  
**Title:** Professor and Chair, Department of Chemical and Petroleum Engineering  
**PHS Funding:** NIH 5 U24 DE026915-02 *Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Lavigen, Inc.  
**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Lavigen, Inc.  
**Approximate dollar value of the SFI:** Consulting income between $20,000 - $39,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**90.**

**Date Disclosed:** February 25, 2019  
**Investigator with FCOI:** Dario A.A. Vignali, PhD  
**Title:** Professor and Vice Chair, Department of Immunology  
**PHS Funding:** NIH 1 R01 AI144422-01 *Structure, Function, and Mechanistic Analysis of LAG3*  
**Role on Research Project:** Principal Investigator of bench and animal research, Co-Investigator of animal research  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Bristol-Myers Squibb  
**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children’s Research Hospital, Inc. and licensed to Bristol-Myers Squibb
Approximate dollar value of the SFI: Aggregate of equity interest and consulting income between $40,000 - $59,999; intellectual property rights between $20,000 - $39,999

91.

Date Disclosed: February 25, 2019
Investigator with FCOI: Dario A.A. Vignali, PhD
Title: Professor and Vice Chair, Department of Immunology
PHS Funding: NIH 1 R01 AI144422-01 Structure, Function, and Mechanistic Analysis of LAG3
Role on Research Project: Principal Investigator of bench and animal research, Co-Investigator of animal research
Name of the Entity in which Significant Financial Interest (SFI) is held: Merck & Co., Inc.
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: $40,000 - $59,999

92.

Date Disclosed: February 28, 2019
Investigator with FCOI: Creg J. Workman, PhD
Title: Research Assistant Professor, Department of Immunology
PHS Funding: NIH 1 R01 AI144422-01 Structure, Function, and Mechanistic Analysis of LAG3
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Johns Hopkins University/St. Jude Children’s Research Hospital, Inc.
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children’s Research Hospital, Inc. and licensed to Bristol-Myers Squibb
Approximate dollar value of the SFI: $20,000 - $39,999

93.

Date Disclosed: March 11, 2019
Investigator with FCOI: William Federspiel, PhD
Title: Professor, Department of Bioengineering
PHS Funding: NIH 5 R01 HL135482-03 Ambulatory Assist Lung for Children
Role on Research Project: Principal Investigator of bench research and Co-Investigator of animal research
Name of the Entity in which Significant Financial Interest (SFI) is held: ALung Technologies, Inc.
Nature of the SFI: Consulting incoming; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ALung Technologies, Inc.
Approximate dollar value of the SFI: Consulting income between $10,000-$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Date Disclosed: April 23, 2019  
Investigator with FCOI: Walter Schneider, PhD  
Title: Professor, Department of Psychology  
PHS Funding: NIH 1 U01 EB026996-01 Connectome 2.0: Developing the Next Generation Human MRI Scanner for Bridging Studies of the Micro-, Meso- and Macro-Connectome  
Role on Research Project: Principal Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Psychology Software Tools, Inc.  
Nature of the SFI: Equity interest  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: May 8, 2019  
Investigator with FCOI: Walter Schneider, PhD  
Title: Professor, Department of Psychology  
PHS Funding: NIH 2 R44 NS103729-02 Advancing and Calibrating Anisotropic Diffusion MR Imaging Brain Connectome with Taxon Brain Network Diffusion Phantoms  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Psychology Software Tools, Inc.  
Nature of the SFI: Equity interest  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: May 17, 2019  
Investigator with FCOI: John Grefenstette, PhD  
Title: Professor, Department of Health Policy and Management  
PHS Funding: NIH 5 P60AA006282-37 (Sub-project ID: 5610) Framework for Behavioral Risk Models of Alcohol Problems  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.  
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.  
Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: May 17, 2019  
Investigator with FCOI: Donald Burke, MD
Title: Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology

PHS Funding: NIH 5 U54GM088491-10 Computational Models of Infectious Disease Threats

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.
Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

98.

Date Disclosed: May 17, 2019
Investigator with FCOI: John Grefenstette, PhD
Title: Professor, Department of Health Policy and Management

PHS Funding: NIH 5 U54GM088491-10 (Sub-project ID: 5080) Models & Forecasts

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.
Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

99.

Date Disclosed: May 23, 2019
Investigator with FCOI: Donald Burke, MD
Title: Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology

PHS Funding: CDC 75D30118C01377 Advancing Analytics to Improve Actionable Changes in the Opioid Overdose Epidemic

Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.
Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

100.

Date Disclosed: May 23, 2019
Investigator with FCOI: John Grefenstette, PhD
Title: Professor, Department of Health Policy and Management
**PHS Funding:** CDC 75D30118C01377 *Advancing Analytics to Improve Actionable Changes in the Opioid Overdose Epidemic*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Epistemix, Inc.

**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.

**Approximate dollar value of the SFI:** Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

101.

**Date Disclosed:** June 11, 2019

**Investigator with FCOI:** Shelby O’Connor, PhD

**Title:** Associate Professor of Pathology and Laboratory Medicine at the University of Wisconsin – Madison

**PHS Funding:** NIH 1R01AI142662 *Effects of HIV SIV on unconventional T cells in immunity to M. tuberculosis in pre adolescents*

**Role on Research Project:** Principal Investigator

**Name of Entity in which Significant Financial Interest (SFI) is held:** Battelle Memorial Institute

**Nature of the SFI:** Consulting

**Approximate dollar value of the SFI:** $5,000 - $9,999

102.  

**FCOI eliminated April 27, 2021**

**Date Disclosed:** June 25, 2019

**Investigator with FCOI:** Joseph Glorioso, PhD

**Title:** Professor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH 5 R01 CA222804-02 *Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Oncorus, Inc.

**Nature of the SFI:** Consulting; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Oncorus

**Approximate dollar value of the SFI:** Consulting income between $100,000 - $149,999; equity interest between $450,000 - $499,999; intellectual property rights is an interest whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

103.  

**FCOI eliminated April 27, 2021**

**Date Disclosed:** June 25, 2019

**Investigator with FCOI:** William Goins, PhD

**Title:** Research Assistant Professor, Department of Microbiology & Molecular Genetics

**PHS Funding:** NIH 5 R01 CA222804-02 *Arming Oncolytic HSV Vectors to Induce Anti-GBM Immune Responses in Syngeneic Mice*
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Oncorus, Inc.  
**Nature of the SFI:** Consulting; equity interest  
**Approximate dollar value of the SFI:** Consulting income between $5,000-$9,999; equity interest between $5,000 - $9,999.

104.  
**Date Disclosed:** June 24, 2019  
**Investigator with FCOI:** Carlos Malvestutto, M.D., M.P.H.  
**Title:** Assistant Professor, Ohio State University  
**PHS Funding:** NIH 5 UM 1AI068619 LOC: HIV Prevention Trials Network  
**Role on Research Project:** Co-Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** ViiV Healthcare  
**Nature of SFI:** Consulting  
**Approximate dollar value:** $10,000 - $19,999

105.  
**Date Disclosed:** July 10, 2019  
**Investigator with FCOI:** Jennifer Grandis, M.D.  
**Title:** Professor and Associate Vice Chancellor for Clinical and Translational Research, University of California, San Francisco  
**PHS Funding:** NIH 5 P50 CA097190-15 Head and Neck Cancer Spore  
**Role on Research Project:** Principal Investigator  
**Name of Entity in which Significant Financial Interest (SFI) is held:** STAT3 Therapeutics  
**Nature of SFI:** Equity interest  
**Approximate dollar value:** $5,000 - $9,999

106.  
**Date Disclosed:** August 8, 2019  
**Investigator with FCOI:** Mark T. Gladwin, MD  
**Title:** Chair, Department of Medicine  
**PHS Funding:** NIH 5 P01 HL103455-09 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease  
**Role on Research Project:** Co-Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Globin Solutions, Inc.  
**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the NIH and licensed to Globin Solutions, Inc.  
**Approximate dollar value of the SFI:** Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
107.

Date Disclosed: August 8, 2019  
Investigator with FCOI: Charles F. McTiernan, PhD  
Title: Research Associate Professor of Medicine, Division of Cardiology  
PHS Funding: NIH 5 P01 HL103455-09 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.  
Nature of the SFI: Equity interest  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

108.

Date Disclosed: October 10, 2019  
Investigator with FCOI: Bruce Freeman, PhD  
Title: Professor and Chair, Department of Pharmacology and Chemical Biology  
PHS Funding: NIH 1 R56 CA233817-01A1 Inhibition of DNA double strand break repair in TNBC by nitro-fatty acids  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.  
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Creegh Pharmaceuticals, Inc.  
Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are unpaid.

109.

Date Disclosed: November 21, 2019  
Investigator with FCOI: Shantanu Chakrabartty, PhD  
Title: Clifford Murphy Professor of Electrical & Systems Engineering at Washington University in St. Louis  
PHS Funding: NIH 1R21AR075242-01 Wireless, Self-Powered Sensors for Continuous and Longer-Term Monitoring of Spinal Fusion Process  
Role on Research Project: Principal Investigator  
Name of Entity in which Significant Financial Interest (SFI) is held: Piezonix, LLC  
Nature of the SFI: Equity interest  
Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

110.

Date Disclosed: December 3, 2019  
Investigator with FCOI: Mark T. Gladwin, MD
Title: Chair, Department of Medicine

PHS Funding: NIH 1 R01 AG058883-01A1 Nitrite Therapy to Improve Mitochondrial Energetics and Physical Activity in Older Adults

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.

Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the NIH and licensed to Globin Solutions, Inc.

Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

111.

Date Disclosed: December 31, 2019

Investigator with FCOI: Charles S. Sfeir, DDS, PhD

Title: Chair, Department of Periodontics and Preventative Dentistry

PHS Funding: NIH 5 U24 DE026915-03 Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Emergence Dental, Inc.

Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Emergence Dental, Inc.

Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are unpaid.

112.

Date Disclosed: February 6, 2020

Investigator with FCOI: Kelly L. Williams, DMD

Title: Assistant Professor, Department of Periodontics and Preventative Dentistry

PHS Funding: NIH 5 U24 DE026915-03 Michigan-Pittsburgh-Wyss Resource Center: Supporting Regenerative Medicine in Dental, Oral and Craniofacial Technologies

Role on Research Project: Co-Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Emergence Dental, Inc.

Nature of the SFI: Consulting; equity interest

Approximate dollar value of the SFI: The interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

113.

Date Disclosed: February 26, 2020

Investigator with FCOI: Tamar Krishnamurti, PhD

Title: Assistant Professor, Division of General Internal Medicine, Department of Medicine
**PHS Funding:** NIH 1 R21 MH119450-01A1 *Identification and Prediction of Peripartum Depression from Natural Language Collected in a Mobile Health App*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Naima Health, LLC

**Nature of the SFI:** Equity interest; management positions; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Carnegie Mellon University and licensed to Naima Health, LLC

**Approximate dollar value of the SFI:** Income from management positions and consulting between $20,000 - $39,999; Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

114.

**Date Disclosed:** February 26, 2020

**Investigator with FCOI:** Hyagriv Simhan, MD, MS

**Title:** Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences

**PHS Funding:** NIH 1 R21 MH119450-01A1 *Identification and Prediction of Peripartum Depression from Natural Language Collected in a Mobile Health App*

**Role on Research Project:** Co-Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Naima Health, LLC

**Nature of the SFI:** Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Naima Health, LLC

**Approximate dollar value of the SFI:** Management position is unpaid; Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

115.

**Date Disclosed:** April 14, 2020

**Investigator with FCOI:** Lee M. Ritterband, Ph.D.

**Title:** Professor, Psychiatry and Neurobehavioral Sciences, University of Virginia

**PHS Funding:** NIH 5 R01 HL131587-03 *Improving Asthma Control Using Internet-Based Cognitive-Behavioral Treatment for Insomnia*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** BeHealth Solutions, LLC

**Nature of the SFI:** Equity interest

**Approximate dollar value of the SFI:** $20,000-39,999

116.

**Date Disclosed:** April 29, 2020

**Investigator with FCOI:** Lori Birder, PhD

**Title:** Professor, Division of Renal-Electrolyte, Department of Medicine

**PHS Funding:** NIH 1 R56 AG063753-01 *Role of Purine Dysregulation in the Underactive Bladder*

**Role on Research Project:** Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Deleon Biosciences, Inc.
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Deleon Biosciences, Inc.
Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: April 29, 2020
Investigator with FCOI: Edwin K. Jackson, PhD
Title: Professor, Department of Pharmacology and Chemical Biology
PHS Funding: NIH 1 R56 AG063753-01 Role of Purine Dysregulation in the Underactive Bladder
Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Deleon Biosciences, Inc.
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Deleon Biosciences, Inc.
Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: June 8, 2020
Investigator with FCOI: Jesus Tejero Bravo, PhD
Title: Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine
PHS Funding: NIH 1 R42 ES031993-01 Hemoglobin-Based Antidotes for the Treatment of Carbon Monoxide Poisoning
Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.
Approximate dollar value of the SFI: Management position income between $5,000 - $9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: June 24, 2020
Investigator with FCOI: Mark T. Gladwin, MD
Title: Chair, Department of Medicine
PHS Funding: NIH 1 R42 ES031993-01 Hemoglobin-Based Antidotes for the Treatment of Carbon Monoxide Poisoning
Role on Research Project: Co-Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.
Approximate dollar value of the SFI: Intellectual property rights and equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

120.

Date Disclosed: July 28, 2020
Investigator with FCOI: Kacey G. Marra, PhD
Title: Professor, Department of Plastic Surgery
PHS Funding: NIH 1 U24 DE029462-01 Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center: Advancing Dental, Oral, and Craniofacial Regeneration to Clinical Trial Initiation
Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: AxoMax Technologies, Inc.
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.
Approximate dollar value of the SFI: Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

121.

Date Disclosed: August 24, 2020
Investigator with FCOI: Samira Kiani, MD
Title: Associate Professor, Department of Pathology
PHS Funding: NIH 7 R01 EB024562-03 CRISPR logic circuits for safer and controllable gene therapies
Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: SafeGen Therapeutics
Nature of the SFI: Equity interest; management position; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Arizona State University and optioned and/or licensed to SafeGen Therapeutics
Approximate dollar value of the SFI: Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

122.

Date Disclosed: August 24, 2020
Investigator with FCOI: Mo Reza Ebrahimkhani, MD
Title: Associate Professor, Department of Pathology  
PHS Funding: NIH 7 R01 EB024562-03 CRISPR logic circuits for safer and controllable gene therapies  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: SafeGen Therapeutics  
Nature of the SFI: Equity interest (held directly by spouse); management position (held directly by spouse): intellectual property rights (e.g., royalties, patents, copyrights) assigned to the Arizona State University and optioned and/or licensed to SafeGen Therapeutics  
Approximate dollar value of the SFI: Management position is unpaid; Intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: August 30, 2020  
Investigator with FCOI: Donald Burke, MD  
Title: Dean Emeritus, Graduate School of Public Health and Professor, Department of Epidemiology  
PHS Funding: CDC 1 U01 IP001141-01 Individual-based Simulation of Seasonal and Pandemic Influenza Epidemics  
Role on Research Project: Co-investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Epistemix, Inc.  
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Epistemix, Inc.  
Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: October 30, 2020  
Investigator with FCOI: Jason J. Rose, MD, MBA  
Title: Assistant Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine  
PHS Funding: NIH 5 R01 HL133003-04 Heme-induced platelet mtROS drives TSP1 release to accelerate PH pathogenesis  
Role on Research Project: Co-investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.  
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.  
Approximate dollar value of the SFI: Management positions income between $10,000-$19,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: November 2, 2020
Investigator with FCOI: George K. Gittes, MD
Title: Chief, Division of Pediatric Surgery, Department of Surgery
PHS Funding: NIH 5 R01 DK112836-04 Endogenous alpha-to-beta cell transdifferentiation in diabetes
Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Genprex, Inc.
Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Genprex, Inc.
Approximate dollar value of the SFI: Consulting income between $20,000-$39,999; intellectual property rights is an interest whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: November 2, 2020
Investigator with FCOI: George K. Gittes, MD
Title: Chief, Division of Pediatric Surgery, Department of Surgery
PHS Funding: NIH 2 R01 DK120377-03 Alpha cell conversion to beta cells in non-human primates
Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Genprex, Inc.
Nature of the SFI: Consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Genprex, Inc.
Approximate dollar value of the SFI: Consulting income between $20,000-$39,999; intellectual property rights is an interest whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: November 20, 2020
Investigator with FCOI: Jesus Tejero Bravo, PhD
Title: Associate Professor of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine
PHS Funding: NIH 5 P01 HL103455-10 Therapeutic Targeting of Vascular Subphenotypes of Lung Disease
Role on Research Project: Co-investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Globin Solutions, Inc.
Nature of the SFI: Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Globin Solutions, Inc.
Approximate dollar value of the SFI: Management position income between $5,000 - $9,999; intellectual property rights and equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: December 2, 2020
Investigator with FCOI: Jason Wilson, MD
Title: Associate Professor, College of Medicine Internal Medicine, University of South Florida
PHS Funding: NIH 1 OT2 HL156812-01 ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center

Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Pfizer, Inc.
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $10,000 - $19,999

Date Disclosed: January 25, 2021
Investigator with FCOI: Jingjing Sun, PhD
Title: Research Instructor, Department of Pharmaceutical Sciences

PHS Funding: NIH 1 R21 CA249649-01A1 Tumor-permeable nanoparticles for enhanced pancreatic cancer immunotherapy

Role on Research Project: Principal Investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Duo Oncology, Inc.
Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Duo Oncology, Inc.
Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: January 25, 2021
Investigator with FCOI: Song Li, MD, PhD
Title: Professor, Department of Pharmaceutical Sciences

PHS Funding: NIH 1 R21 CA249649-01A1 Tumor-permeable nanoparticles for enhanced pancreatic cancer immunotherapy

Role on Research Project: Co-investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Duo Oncology, Inc.
Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Duo Oncology, Inc.
Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: February 17, 2021
Investigator with FCOI: Jan Drappatz, MD
Title: Associate Professor, Department of Neurology

PHS Funding: NIH 5 UM1 CA137443-10 Adult Brain Tumor Consortium (ABTC)
Role on Research Project: Co-investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Bristol-Myers Squibb
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: $20,000 - $39,999

Date Disclosed: March 12, 2021
Investigator with FCOI: Bruce Freeman, PhD
Title: Professor and Chair, Department of Pharmacology and Chemical Biology
PHS Funding: NIH 1 R21 HL152312-01A1 Focal delivery of nitro-oleic acid using ultrasound targeted microbubble cavitation for the treatment of microvascular obstruction
Role on Research Project: Co-investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.
Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Creegh Pharmaceuticals, Inc.
Approximate dollar value of the SFI: Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: March 25, 2021
Investigator with FCOI: Robert M.O. Shanks, PhD
Title: Associate Professor, Department of Ophthalmology
PHS Funding: NIH 3 R01 EY027331-04S1 NOT-N5-20-030: Use of anchored biologics to treat vesicant induced neovascularization
Role on Research Project: Principal Investigator

Name of the Entity in which Significant Financial Interest (SFI) is held: AnkyrBio LLC
Nature of the SFI: Equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to AnkyrBio LLC
Approximate dollar value of the SFI: Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Date Disclosed: March 25, 2021
Investigator with FCOI: Jes K. Klarlund, PhD
Title: Adjunct Associate Professor, Department of Ophthalmology
PHS Funding: NIH 3 R01 EY027331-04S1 NOT-N5-20-030: Use of anchored biologics to treat vesicant induced neovascularization
Role on Research Project: Co-investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: AnkyrBio LLC
Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to AnkyrBio LLC

**Approximate dollar value of the SFI:** Management position income between $60,000 - $79,999; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

135.

**Date Disclosed:** April 1, 2021  
**Investigator with FCOI:** Sanjay Mathew, MD  
**Title:** Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine  
**PHS Funding:** NIH 5 R01 MH113857-04 Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Alkermes  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $60,000 - $79,999

136.

**Date Disclosed:** April 1, 2021  
**Investigator with FCOI:** Sanjay Mathew, MD  
**Title:** Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine  
**PHS Funding:** NIH 5 R01 MH113857-04 Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Allergan  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $5,000 - $9,999

137.

**Date Disclosed:** April 1, 2021  
**Investigator with FCOI:** Sanjay Mathew, MD  
**Title:** Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine  
**PHS Funding:** NIH 5 R01 MH113857-04 Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Intra-Cellular Therapies, Inc.  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $5,000 - $9,999
138.

Date Disclosed: April 1, 2021  
Investigator with FCOI: Sanjay Mathew, MD  
Title: Professor, Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine  
PHS Funding: NIH 5 R01 MH113857-04 Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition  
Role on Research Project: Principal Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Janssen Research and Development  
Nature of the SFI: Consulting  
Approximate dollar value of the SFI: $20,000 - $39,999

139.

Date Disclosed: April 15, 2021  
Investigator with FCOI: Stephen Y. Chan, MD, PhD  
Title: Professor, Division of Cardiology, Department of Medicine  
PHS Funding: NIH 5 R01 HL138437-04 Molecular Drivers of Vascular Stiffness and Metabolic Dysfunction in HIV-Induced Pulmonary Arterial Hypertension  
Role on Research Project: Principal Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: Synhale Therapeutics, Inc.  
Nature of the SFI: Management positions; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and University of Pittsburgh/Brigham Woman’s Hospital and optioned to Synhale Therapeutics, Inc.  
Approximate dollar value of the SFI: Management positions are unpaid; equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

140.

Date Disclosed: May 20, 2021  
Investigator with FCOI: Stephen F. Badylak, DMV, PhD, MD  
Title: Professor, Department of Surgery and Deputy Director of the McGowan Institute for Regenerative Medicine (MIRM)  
PHS Funding: NIH 1 R21 NS118399-01A1 Enhancing Neurogenesis for Brain Tissue Regeneration  
Role on Research Project: Co-investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: ECM Therapeutics, Inc.  
Nature of the SFI: Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to ECM Therapeutics, Inc.  
Approximate dollar value of the SFI: Management position income between $100,000 - $149,999; equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
141.

**Date Disclosed:** May 24, 2021  
**Investigator with FCOI:** Robert Desnick, PhD, MD, DSc  
**Title:** Professor & Chair Emeritus, Genetics and Genomic Sciences, Mount Sinai School of Medicine  
**PHS Funding:** NIH 1 R01 DK124412-01A1 *Beta-catenin inhibition as a novel therapeutic strategy for porphyria*  
**Role on Research Project:** Co-investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Alnylam Pharmaceuticals  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $20,000 - $39,999

142.

**Date Disclosed:** July 21, 2021  
**Investigator with FCOI:** Lillian Chong  
**Title:** Associate Professor, Department of Chemistry  
**PHS Funding:** NIH 5 R01 GM115805-07 *High-performance weighted ensemble software for simulation of complex bio-events*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** OpenEye Scientific  
**Nature of the SFI:** Consulting  
**Approximate dollar value of the SFI:** $20,000 - $39,999

143.

**Date Disclosed:** August 11, 2021  
**Investigator with FCOI:** Mark E. Schurdak, PhD  
**Title:** Visiting Research Associate Professor, Department of Computational & Systems Biology  
**PHS Funding:** NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** BioSystics, Inc.  
**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to BioSystics, Inc.  
**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

144.

**Date Disclosed:** August 11, 2021  
**Investigator with FCOI:** Albert Gough, PhD  
**Title:** Research Associate Professor, Department of Computational & Systems Biology
**PHS Funding:** NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*

**Role on Research Project:** Principal Investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** BioSystics, Inc.

**Nature of the SFI:** Management position; equity interest; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to BioSystics, Inc.

**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

---

**Date Disclosed:** August 11, 2021

**Investigator with FCOI:** D. Lansing Taylor, PhD

**Title:** Professor, Department of Computational & Systems Biology

**PHS Funding:** NIH 2 U24 TR002632-03 *Development and Commercialization of the Microphysiological Systems Database as a Sustainable Resource*

---

**Date Disclosed:** August 24, 2021

**Investigator with FCOI:** Leah Byrne, PhD

**Title:** Assistant Professor, Department of Ophthalmology

**PHS Funding:** NIH 5 UG3 MH120094-03 *A Massive Library of AAVs to Target Transcriptionally-Defined Primate Cell Types*

---

**Role on Research Project:** Co-investigator

**Name of the Entity in which Significant Financial Interest (SFI) is held:** Newsight Therapeutics

**Nature of the SFI:** Management position; equity interest

**Approximate dollar value of the SFI:** Equity interest (including such interest received as compensation for management position services) are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
147.

**Date Disclosed:** November 16, 2021  
**Investigator with FCOI:** Samira Kiani, MD  
**Title:** Associate Professor, Department of Pathology  
**PHS Funding:** NIH 5 R01 EB024562-04 *CRISPR logic circuits for safer and controllable gene therapies*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** GenexGen Inc.  
**Nature of the SFI:** Equity interest; management position  
**Approximate dollar value of the SFI:** Management position is unpaid; equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

148.

**Date Disclosed:** December 15, 2021  
**Investigator with FCOI:** Charles S. Sfeir, DDS, PhD  
**Title:** Chair, Department of Periodontics and Preventative Dentistry  
**PHS Funding:** NIH 2 R44DE024919-05 *Commercialization Readiness Program (CRP) for Bioabsorbable Magnesium (Mg) Implants for Craniofacial Surgical Systems*  
**Role on Research Project:** Principal Investigator  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Emergence Dental, Inc.  
**Nature of the SFI:** Equity interest; management positions; intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and optioned to Emergence Dental, Inc.  
**Approximate dollar value of the SFI:** Equity interest and intellectual property rights are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are unpaid.

149.

**Date Disclosed:** February 7, 2022  
**Investigator with FCOI:** Dario A.A. Vignali, PhD  
**Title:** Professor and Vice Chair, Department of Immunology  
**PHS Funding:** NIH 1 P50 CA254865-01A1 *Melanoma and Skin Cancer SPORE*  
**Role on Research Project:** Principal Investigator of bench research  
**Name of the Entity in which Significant Financial Interest (SFI) is held:** Bristol-Myers Squibb  
**Nature of the SFI:** Equity interest; consulting; intellectual property rights (e.g., royalties, patents, copyrights) assigned to Johns Hopkins University/St. Jude Children’s Research Hospital, Inc. and licensed to Bristol-Myers Squibb  
**Approximate dollar value of the SFI:** Aggregate of equity interest and consulting income between $20,000 - $29,999; intellectual property rights between $80,000 - $99,999
150.

Date Disclosed: February 8, 2022
Investigator with FCOI: Nick Allen, PhD
Title: Professor; Department of Psychology; University of Oregon
PHS Funding: NIH 1 R01 MH125971-01 Early Intervention for Youth At-Risk for Bipolar Disorder
Role on Research Project: Co-investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Ksana Health
Nature of the SFI: Equity interest; management position
Approximate dollar value of the SFI: Equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value. Management positions are $20,000 - $39,999.

151.

Date Disclosed: February 8, 2022
Investigator with FCOI: Robert Gaunt
Title: Associate Professor, Department of Physical Medicine and Rehabilitation
PHS Funding: NIH 5 UH3 NS107714-03 A Biomimetic Approach Towards a Dexterous Neuroprostheses
Role on Research Project: Co-investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Blackrock Microsystems, LLC
Nature of the SFI: Consulting
Approximate dollar value of the SFI: $100,000 - $149,999

152.

Date Disclosed: March 21, 2022
Investigator with FCOI: Louis D. Falo, Jr., M.D., Ph.D.
Title: Professor and Chair of Dermatology
PHS Funding: NIH 1 P50 CA254865-01A1 (Sub-project ID: 5877) SPORE in Skin Cancer
Role on Research Project: Principal Investigator of bench and Co-Investigator of human subject, research
Name of Entity in which Significant Financial Interest (SFI) is held: SkinJect
Nature of the SFI: Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to SkinJect; equity interest
Approximate dollar value of the SFI: IP - $5,000 - $9,999; Equity - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
153.

**Date Disclosed:** April 22, 2022  
**Investigator with FCOI:** Charles Jonassaint, PhD MHS.  
**Title:** Assistant Professor of Medicine, Social Work and Clinical and Translational Science  
**PHS Funding:** NIH 5 UH3 HL143192-03  *1/2 Sickle Cell Disease and CardioVAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)*  
**Role on Research Project:** Co-Investigator of human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Expressive Painimation  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Expressive Painimation; equity interest; management position  
**Approximate dollar value of the SFI:** Equity/IP/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

154.

**Date Disclosed:** April 25, 2022  
**Investigator with FCOI:** Charles Jonassaint, PhD MHS.  
**Title:** Assistant Professor of Medicine, Social Work and Clinical and Translational Science  
**PHS Funding:** NIH 1 RM1 DA055311-01  *Tailored Retention and Engagement for Equitable Treatment of OUD and Pain (TREETOP)*  
**Role on Research Project:** Co-Investigator of human subject, research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Expressive Painimation  
**Nature of the SFI:** Intellectual property rights (e.g., royalties, patents, copyrights) assigned to the University of Pittsburgh and licensed to Expressive Painimation; equity interest; management position  
**Approximate dollar value of the SFI:** Equity/IP/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

155.

**Date Disclosed:** May 9, 2022  
**Investigator with FCOI:** Joseph C. Glorioso III, PhD  
**Title:** Professor of Microbiology and Molecular Genetics  
**PHS Funding:** NIH 1 UG3 NS123964-01  *Disease Modifying Analgesia with CA8 Gene Therapy*  
**Role on Research Project:** Principal investigator of bench research  
**Name of Entity in which Significant Financial Interest (SFI) is held:** Adolore Therapeutics, Inc.  
**Nature of the SFI:** Equity interest; management position  
**Approximate dollar value of the SFI:** Equity/management position - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
156.

Date Disclosed: May 9, 2022  
Investigator with FCOI: Joseph C. Glorioso III, PhD  
Title: Professor of Microbiology and Molecular Genetics  
PHS Funding: NIH 1 UG3 NS123964-01 Disease Modifying Analgesia with CA8 Gene Therapy  
Role on Research Project: Principal investigator of bench research  
Name of Entity in which Significant Financial Interest (SFI) is held: RePlay Holdings LLC  
Nature of the SFI: Equity interest; consulting  
Approximate dollar value of the SFI: Equity - The interests are ones whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value; consulting - $100,000 - $149,999

157.

Date Disclosed: May 11, 2022  
Investigator with FCOI: Yi Shi, PhD  
Title: Associate Professor, Director for Center of Protein Engineering and Therapeutics; Icahn School of Medicine at Mount Sinai  
PHS Funding: NIH 1 R21 CA261737-01 Using nanobodies to increase the sensitivity and resolution of chromatin profiling through uliCUT&RUN  
Role on Research Project: Principal investigator of bench research  
Name of the Entity in which Significant Financial Interest (SFI) is held: Antenna Biotechnology, Inc.  
Nature of the SFI: Equity interest  
Approximate dollar value of the SFI: Equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

158.

Date Disclosed: July 27, 2022  
Investigator with FCOI: Mo Reza Ebrahimkhani, MD  
Title: Associate Professor, Department of Pathology  
PHS Funding: NIH 5 R01 EB 024562-04 CRISPR logic circuits for safer and controllable gene therapies  
Role on Research Project: Co-Investigator  
Name of the Entity in which Significant Financial Interest (SFI) is held: GenexGen  
Nature of the SFI: Equity interest; management position  
Approximate dollar value of the SFI: Management position is unpaid; Equity interest are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Date Disclosed: August 3, 2022
Investigator with FCOI: Marco Fazzari, PhD
Title: Assistant Professor, Department of Pharmacology and Chemical Biology
PHS Funding: NIH 5 R21 HL152312-02 *Focal delivery of nitro-oleic acid using ultrasound targeted microbubble cavitation for the treatment of microvascular obstruction*
Role on Research Project: Co-investigator
Name of the Entity in which Significant Financial Interest (SFI) is held: Creegh Pharmaceuticals, Inc.
Nature of the SFI: Equity interest
Approximate dollar value of the SFI: Equity interest values are SFIs whose values cannot be readily determined through reference to public prices or other reasonable measures of fair market value.